Candel Therapeutics Inc

詳細情報 Candel Therapeutics Inc 企業名

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.

企業情報

企業コードCADL

会社名Candel Therapeutics Inc

上場日Jul 27, 2021

最高経営責任者「CEO」Dr. Paul Peter Tak, M.D., Ph.D.

従業員数38

証券種類Ordinary Share

決算期末Jul 27

本社所在地117 Kendrick Street,

都市NEEDHAM

証券取引所NASDAQ Global Market Consolidated

国United States of America

郵便番号02494

電話番号16179165445

ウェブサイトhttps://www.candeltx.com/

企業コードCADL

上場日Jul 27, 2021

最高経営責任者「CEO」Dr. Paul Peter Tak, M.D., Ph.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Christopher (Chris) Martell

Independent Director

435.51K

--

Dr. Paul Peter Tak, M.D., Ph.D.

President, Chief Executive Officer, Director

268.57K

+18.97%

Dr. Francesca Barone, M.D., Ph.D.

Chief Scientific Officer

100.81K

+4.44%

Mr. Charles Schoch

Chief Financial Officer

43.39K

+14.07%

Mr. Joseph C. (Joe) Papa

Independent Director

38.03K

--

Dr. Diem Nguyen, Ph.D.

Independent Director

10.00K

--

Dr. Edward J. Benz, Jr., M.D.

Independent Director

--

Ms. Seshu Tyagarajan, Ph.D.

Chief Technical and Development Officer

--

Mr. Paul B. Manning

Independent Chairman of the Board

--

Dr. W. Garrett Nichols, M.D.

Chief Medical Officer

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Christopher (Chris) Martell

Independent Director

435.51K

--

Dr. Paul Peter Tak, M.D., Ph.D.

President, Chief Executive Officer, Director

268.57K

+18.97%

Dr. Francesca Barone, M.D., Ph.D.

Chief Scientific Officer

100.81K

+4.44%

Mr. Charles Schoch

Chief Financial Officer

43.39K

+14.07%

Mr. Joseph C. (Joe) Papa

Independent Director

38.03K

--

Dr. Diem Nguyen, Ph.D.

Independent Director

10.00K

--

収益内訳

FY2024

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q3

データなし

地域別USD

会社名

収益

比率

United States

0.00

0.00%

事業別

地域別

データなし

株主

更新時刻: Sat, May 24

株主統計

種類

株主統計

比率

Fidelity Management & Research Company LLC

13.50%

Manning (Paul B.)

5.38%

Acorn Capital Advisors, LLC

4.92%

Baker Bros. Advisors LP

4.64%

Aguilar-Cordova (Estuardo)

4.61%

Other

66.94%

株主統計

比率

Fidelity Management & Research Company LLC

13.50%

Manning (Paul B.)

5.38%

Acorn Capital Advisors, LLC

4.92%

Baker Bros. Advisors LP

4.64%

Aguilar-Cordova (Estuardo)

4.61%

Other

66.94%

種類

株主統計

比率

Investment Advisor

29.01%

Individual Investor

16.48%

Investment Advisor/Hedge Fund

6.21%

Hedge Fund

5.99%

Corporation

2.48%

Research Firm

0.64%

Bank and Trust

0.09%

Pension Fund

0.02%

Insurance Company

0.02%

Other

39.06%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

162

31.98M

60.95%

-104.17K

2025Q1

160

30.10M

67.51%

-1.81M

2024Q4

131

27.38M

62.24%

+9.09M

2024Q3

115

17.10M

48.26%

-703.44K

2024Q2

98

16.89M

49.23%

+872.97K

2024Q1

67

14.85M

50.59%

-1.40M

2023Q4

65

14.94M

51.56%

-1.48M

2023Q3

68

15.61M

53.96%

-846.00K

2023Q2

65

15.70M

54.30%

-590.47K

2023Q1

64

16.17M

55.93%

-250.07K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Fidelity Management & Research Company LLC

7.09M

13.5%

+766.60K

+12.13%

Mar 31, 2025

Manning (Paul B.)

2.82M

5.38%

+500.00K

+21.52%

Apr 21, 2025

Acorn Capital Advisors, LLC

2.58M

4.92%

+428.26K

+19.90%

Jun 25, 2025

Baker Bros. Advisors LP

2.44M

4.64%

-544.79K

-18.27%

Mar 31, 2025

Aguilar-Cordova (Estuardo)

2.42M

4.61%

+190.92K

+8.57%

Apr 21, 2025

Aguilar (Laura K)

2.36M

4.49%

-690.05K

-22.65%

Apr 21, 2025

The Vanguard Group, Inc.

1.74M

3.31%

+396.95K

+29.64%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

1.61M

3.06%

+515.63K

+47.27%

Mar 31, 2025

BKB Growth Investments LLC

1.30M

2.48%

+750.00K

+135.44%

Apr 21, 2025

Portolan Capital Management, L.L.C.

881.18K

1.68%

+127.44K

+16.91%

Mar 31, 2025

詳細を見る

6.265USD

Candel Therapeutics Inc

6.265

概要

企業名

金融